期刊文献+

UbcH10在乳腺浸润性导管癌中的表达及预后分析 被引量:3

Expression of UbcH10 correlates with prognosis of infiltrating ductal carcinoma of breast
下载PDF
导出
摘要 目的:探讨UbcH10在乳腺浸润性导管癌中的表达及其与预后的关系。方法:采用免疫组化检测100例乳腺浸润性导管癌组织中UbcH10、ER、PR、Ki-67、p53和HER-2的表达差异,分析UbcH10表达与年龄、TNM分期、分化程度、ER、PR、Ki-67、p53表达及HER-2等特征及预后的相关性。结果:UbcH10在乳腺浸润性导管癌中高表达,在乳腺癌组织与癌旁组织及乳腺良性肿瘤中的表达存在显著差异;UbcH10的表达在不同分化程度之间和乳腺癌各分子分型之间有统计学差异;UbcH10的表达与Ki-67、HER-2表达有相关性;UbcH10的表达与病人年龄、肿块大小、区域淋巴结转移、肿瘤TNM分期、ER、PR、p53表达状态无相关性;UbcH10高表达组预后差,阳性表达的生存时间低于阴性表达。结论:UbcH10在乳腺浸润性导管癌中高表达,预后较差。 Objective To investigate the correlation between the expression of UbcH10 and the prognosis of infiltrating ductal carcinoma of breast. Methods Immunohistochemistry was used to measure the levels of expression of UbcH10, ER, PR, Ki-67, p53 and HER-2 in 100 cases with infiltrating ductal carcinoma of breast and to analyze the correlation between the expression of UbcH10 with the patients'age, TNM stage, degree of differentiation, and expression of ER, PR, Ki-67, p53 and HER-2. Results The different expression of UbcH10 has statistical difference among the different degree of differentiation in the infiltrating ductal carcinoma of breast and also among the different molecular types of breast cancer. The expression of UbcH10 had correlation with the expression of Ki=67 and HER-2. No difference was present for the expression of UbcH10 with patients' age, tumor size, regional lymph node invasion, TNM stage and the expression of ER, PR and p53 in infiltrating ductal carcinoma of breast. The prognosis was worse in the patients with high expression of UbcH10 in infiltrating ductal carcinoma of breast. Conclusions UbcH10 was higher expression in infiltrating ductal carcinoma of breast and the 13rognosis is worse.
出处 《外科理论与实践》 2014年第1期47-52,共6页 Journal of Surgery Concepts & Practice
关键词 乳腺癌 UBCH10 预后 KI-67 HER-2 Breast cancer UbcH10 Prognosis Ki-67 HER-2
  • 相关文献

同被引文献65

  • 1邵志敏,沈镇宙,徐兵河,主编.乳腺肿瘤学[M].上海:复旦大学出版社,2013: 24-25.
  • 2Donato G, Iofrida G, Lavano A, et al. Analysis of UbeH10 expres- sion represents a useful tool for the diagnosis and therapy of astroey- tie tumors [ J ]. Clin Neuropathol, 2008, 27 (4) : 219 - 223.
  • 3Berlingieri MT, Pallante P, Guida M, et al. UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas[J]. Oncogene, 2007, 26(14) : 2136 - 2140.
  • 4Ieta K, Ojima E, Tanaka F, et al. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin- conjugating enzyme E2C gene expression[ J]. Int J Cancer, 2007, 121(1): 33-38.
  • 5Fujita T, Ikeda H, Kawasaki K, et al. Clinicopathological relevance of UbcH10 in breast cancer[J]. Cancer Sci, 2008, 100 (2): 238 - 248.
  • 6Aristarkhov A, Eytan E, Moghe A ubiquitin carrier protein required cyclones[J]. Proc Natl Acad Sci , et al. E2-C, a eyclin selective for the destruction of mitotic U S A, 1996, 93(9): 4294- 4299.
  • 7Lin Y, Hwang WC, Basavappa R. Structural and functional analysis of the human mitotic-specific ubiquitin conjugating enzyme,UbcH10 J]. JBiol Chem, 2002, 277(24): 21913 -21921.
  • 8Townsley FM, Aristarkhov A, Beck S, et al. Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase[J]. Proc Natl Acad Sci U S A, 1997, 94(6): 2352 - 2367.
  • 9Okamoto Y, Ozaki T, Miyazaki K, et al. UbchlO is the cancer- related E2 ubiqutin-conjugating enzyme[ J]. Cancer Res, 2003, 63 (64) : 4167 -4173.
  • 10Berlingieri MT, Pallante P, Sboner A, et al. UbcH10 is overex- pressed in malignant breast carcinomas [ J]. Eur J Cancer, 2007, 43 ( 18 ) : 2729 - 2735.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部